"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Original article
peer-reviewed

# Association Between Marijuana Use and Cardiovascular Disease in US Adults

### Abstract

#### Introduction

The prevalence of marijuana use has increased by about 16% since 2006, translating to approximately 200 million people worldwide. Being so widely used, long-term effects of marijuana use on cardiovascular health are largely unknown. Previous studies have had conflicting results, either showing marijuana use having a negative impact or no significant impact on cardiovascular health. This study aims to add evidence regarding the impact marijuana use has on the prevalence of cardiovascular disease.

#### Methods

This retrospective study was conducted using the Behavioral Risk Factor Surveillance System (BRFSS) database. Patients who completed the questionnaire and answered all questions in relation to marijuana use and the diagnosis of cardiovascular disease in 2017 were a part of this study. Subjects were excluded if they were children (<18 years old) or had missing data for marijuana use or cardiovascular disease. Age, gender, race/ethnicity, body mass index (BMI), income, exercise, tobacco use, alcohol use, and depression were all considered as potential confounders. Bivariate analysis was conducted to find an initial association between marijuana use and cardiovascular disease, which was followed by a multivariate regression analysis to adjust for confounders. Odds ratios and 95% confidence intervals were calculated.

#### Results

A total of 56,742 subjects were included in the analysis. The unadjusted bivariate analysis showed a reduced prevalence of cardiovascular disease in individuals using marijuana (OR 0.65, 95%CI [0.50-0.84]). After adjustment with all additional variables, an adjusted model showed a similar odds ratio, but statistical significance of the association was lost (OR 0.74, 95%CI [0.54-1.01]).

#### Discussion

A systematic review by Ravi et al in 2018, which looked at marijuana use, cardiovascular risk factors, and clinical outcomes concluded that there was insufficient data to make conclusions regarding the effect of marijuana use and negative long-term cardiovascular effects. Our study lends support to the notion that marijuana use does not have an association with cardiovascular disease. A limitation in our study was that there was missing data from the BRFSS questionnaire due to participants not fully answering all questions concerning cardiovascular disease and marijuana use. This decreased our sample size from 67,974 to 56,742 subjects. The missing participants led to a decrease in the power of our odds ratio, which may have impacted statistical significance of our results.

#### Conclusion

Although previous literature has shown that marijuana use has a negative impact on cardiovascular health, our study suggests that users and non-users of marijuana did not have an association with the prevalence of cardiovascular disease. Varying levels of support within the literature highlights the need for further research of this association.

### Introduction

Marijuana is a widely known psychoactive flowering plant that is being used both recreationally and for medicinal purposes. The prevalence of marijuana use has increased by about 16% since 2006, translating to approximately 200 million people worldwide [1]. With this substance use being increasingly prevalent, especially within the scope of medical therapeutics, it is crucial to have evidence about the long-term effects of marijuana use on cardiovascular diseases, as it has been shown in multiple studies to have an effect on blood pressure, heart function, and sympathetic drive [1-4]. Currently, there is very mixed evidence about the impact of marijuana use and subsequent cardiovascular issues. Some note that marijuana use can acutely increase blood pressure for two to five hours as well as increase cardiac output by more than 30% [2]. There are also suggestions that the onset of myocardial infarction (MI) increases in the first 60 minutes after marijuana consumption [5]. Furthermore, in daily marijuana users, the annual risk of MI increases from 1.5% to 3.0% per year. Through both human and animal trials, it is suggested that this may be due to coronary artery vasospasm induced by marijuana use [3]. Lastly, a systematic review published in February of 2018 concluded that while there have been studies done that have found associations between cardiovascular risk factors and marijuana use, there is insufficient evidence to conclude anything regarding this link [4]. With such varied results from multiple peer-reviewed articles, there is not a clear picture of how marijuana use impacts cardiovascular health. Through this project, we hope to add evidence to the association between marijuana use and cardiovascular disease. This aims to pinpoint any demographic characteristics or combinations of risk factors that positively or negatively impact patient health.

### Materials & Methods

This retrospective cross-sectional study was conducted using data from the 2017 Behavioral Risk Factor Surveillance System (BRFSS) annual report. The BRFSS collects data via telephone surveys given in all 50 states and three US territories. It used a random sample, as telephone numbers were gathered via a random number generator. The initial sample was filtered to include US adults (above 18 years) from states that asked each subject a relevant question in the survey regarding marijuana use. States that are part of this study included: Alaska, California, Georgia, Idaho, Minnesota, New Hampshire, South Carolina, Tennessee, and Wyoming. These were the only states included as the survey questions regarding marijuana use were asked exclusively in these nine states. Subjects were excluded from this sample if they had any incomplete data regarding marijuana use, cardiovascular disease, or both.

The primary exposure for the study was marijuana use. Within the database marijuana use was assessed by asking: “During the past 30 days, on how many days did you use marijuana or cannabis?”. Data were summarized into two categories: “yes” if a subject answered any number > 0, or “no” if the subject answered 0. Our primary outcome was the prevalence of cardiovascular disease. Questions associated with the prevalence of cardiovascular disease included: “Has a doctor, nurse, or other health professional ever told you that you had a heart attack also called a myocardial infarction?”, “(Ever told) you had angina or coronary heart disease?”, and “(Ever told) you had a stroke?”. Subjects that answered “no” to all 3 questions were designated as not having cardiovascular disease, while those answering “yes” to any of them were considered otherwise. Additional variables that factored as potential covariates included: age (<65 years old, ≥ 65 years old), gender (Male, Female), race/ethnicity (White only, Black/African American only, Asian only, Other, Multiracial, Hispanic), body mass index (BMI) (underweight [BMI<18.5], normal weight [BMI 18.5-24.99], overweight [BMI 25-29.99], obese [BMI ≥30]), annual household income (< $25,000,$25,000-49,999, $50,000-74,999, >$75,000), exercise in past 30 days (yes/no), tobacco use defined as 100 or more cigarettes over entire life (smoker/non-smoker), alcohol use in the past 30 days (yes/no), and medically diagnosed depression (yes/no).

All analysis was conducted using STATA version 14 (StataCorp., College Station, TX). First, chi-square tests were performed to analyze the distribution of baseline characteristics (i.e., age, gender, race/ethnicity, BMI, income, exercise, tobacco use, alcohol use, depression) in relation to marijuana use. The associations between marijuana use and cardiovascular disease, as well as among other baseline features and cardiovascular disease, were then assessed using bivariate analysis. A multivariate logistic regression was conducted to determine and control for potential covariates on the association between the primary exposure and the outcome. Odds ratios and 95% confidence intervals were computed to quantitatively express any association. Lastly, because many eligible participants were ultimately excluded due to missing data, we conducted best-case and worst-case scenarios for the missing subjects, placing all missing subjects either in the non-marijuana user or marijuana user categories, respectively. Furthermore, baseline features between subjects in the study and missing subjects were also compared.

### Results

The 2017 BRFSS annual report included 67,974 participants. Subjects were excluded from this initial sample if they had any incomplete data regarding marijuana use cardiovascular disease, or both. In total, 11,232 subjects were excluded applying these criteria, leaving a final sample size of 56,742 individuals (Figure 1).

Among our sample, the overall prevalence of marijuana use was calculated as 3,412 out of 56,742 subjects (6.0%) (Table 2). When analyzing the baseline characteristics of our sample, all but 2 of our covariates demonstrated a statistically significant difference between those who used marijuana versus those who did not (Table 1). Younger age (<65 years old) was more common in marijuana users (93.2%) versus non-marijuana users (77.1%). Marijuana users were also more commonly male (63.1%) and reported exercising more (80.7%). The frequency of tobacco use was significantly higher in marijuana users (58.6%) versus non-marijuana users (35.5%). Furthermore, marijuana users tended to answer yes to screening questions on depression (31.1%) versus non-marijuana users (17.4%). When examining overweight and obese individuals via body mass index, 32% of overweight individuals and 20.8% of obese individuals used marijuana. A higher percentage of marijuana users consumed alcohol (40.0%) when compared to non-marijuana users (13.1%). Both the variables of race/ethnicity and income status did not show a statistically significant difference (p<0.001) between the two groups.

 Characteristics Marijuana Use p-value No Yes N % N % Age <65 years old 33,197 77.1 2,989 93.2 <0.001 65 years or older 19,548 22.9 409 6.8 Gender Male 23,090 46.4 2,147 63.1 <0.001 Female 30224 53.6 1,264 36.9 Race/Ethnicity White 41,205 55.7 2,403 55.8 0.0145 Black/African American 4723 10.7 292 12.8 Asian 902 9.1 57 6.6 Other 1,131 1.5 171 2.2 Multiracial 813 1.4 122 2.3 Hispanic 3,547 21.6 302 20.3 BMI Underweight (<18.5) 752 1.92 92 2.6 <0.001 Normal weight (18.5-24.99) 15,109 31.9 1,341 44.6 Overweight (25-29.99) 18,123 36.2 1,147 32.0 Obese (≥30) 15,705 30 771 20.8 Income < 25,000 11,408 27.7 1,026 28.8 0.4345 25,000-49,999 11,125 22 724 19.7 50,000-74,999 7,410 14.6 469 14.5 ≥75,000 15,558 35.7 875 37.0 Exercise + 38,537 74.9 2,624 80.7 <0.001 0 14,419 25.1 770 19.3 Tobacco use + 21,908 35.5 2,277 58.6 <0.001 0 31,134 64.5 1,125 41.4 Alcohol use + 5,964 13.1 1,345 40.0 <0.001 0 46,542 86.9 1,994 60.0 Depression + 10,163 17.4 1,180 31.1 <0.001 0 42,953 82.6 2,204 68.9

Table 2 shows the prevalence of cardiovascular disease among individuals within our sample. Overall, 11.2% (N = 6,353) of the sample reported some form of cardiovascular disease. Relating it to the exposure, 5.5% of subjects that use marijuana reported having cardiovascular disease, as compared to 8.2% among non-marijuana users. As expected, older individuals (>65 years old) showed a higher prevalence (19.9% vs. 4.7%) of cardiovascular disease when compared to their younger counterparts. The overall prevalence of cardiovascular disease was highest in multiracial and other race groups (10.6% and 10.9%, respectively), followed closely by that in whites (9.8%). Other baseline characteristics showed the expected association with cardiovascular disease. Those with higher BMIs, lower income, no exercise, tobacco use, alcohol use, and depression all had a significantly higher prevalence of cardiovascular disease (p < 0.001).

 Characteristics Cardiovascular Disease p-value No Yes N % N % N Marijuana Use 0 47,259 91.8 6,071 8.2 <0.001 + 3,130 94.5 282 5.5 Age <65 years old 34,016 95.3 2,170 4.7 <0.001 65 years or older 15,827 80.1 4,130 19.9 Gender Male 21,899 90.6 3,338 9.4 <0.001 Female 28,476 93.4 3,012 6.6 Race/Ethnicity White only 38,605 90.3 5,003 9.8 <0.001 Black/African American only 4,376 91.8 639 8.2 Asian only 934 96.8 25 3.2 Other 1,125 89.1 177 10.9 Multiracial 804 89.4 131 10.6 Hispanic 3,636 95.5 213 4.5 BMI Underweight 730 94.2 114 5.8 <0.001 Normal weight 14,949 94.1 1,501 5.9 Overweight 17,099 91.5 2,171 8.5 Obese 14,216 89.6 2,260 10.4 Income < 25,000 10,235 87.9 2,199 12.1 <0.001 25,000-49,999 10,463 91.5 1,386 8.5 50,000-74,999 7,121 93.5 758 6.5 At least 75,000 15,453 95.1 980 4.9 Exercise + 37,313 93.3 3,848 6.7 <0.001 0 12,733 88.3 2,456 11.7 Tobacco use + 20,381 87.5 3,804 12.5 <0.001 0 29,745 94.8 2,514 5.2 Alcohol use + 6,936 95.5 373 4.5 <0.001 0 42,652 91.4 5,884 8.6 Depression + 9,537 86.6 1,806 13.4 <0.001 0 40,649 93.3 4,508 6.7

The unadjusted odds ratio of cardiovascular disease with marijuana use was statistically significant 0.65 (95% CI: 0.50-0.84) compared to those who did not use marijuana (Table 3). When adjusting for age, gender, race/ethnicity, BMI, income, exercise, tobacco use, alcohol use, and depression, the odds ratio was 0.74 (95% CI: 0.54-1.01), which was not statistically significant. The other variables that were strongly associated with cardiovascular disease after adjustment were age (>65 years old), income (<\$25,000 per year), and depression. These variables each had an odds ratio > 2 (Table 3).

 Characteristics Unadjusted Adjusted OR (95% CI) p-value OR (95% CI) p-value Marijuana Use 0.65 (0.50-0.84) 0.001 0.74 (0.54-1.01) 0.059 Age > 65 years 5.03 (4.44-5.70) <0.001 4.36 (3.70-5.13) <0.001 Female Sex 0.68 (0.60-0.76) <0.001 0.50 (0.42-0.58) <0.001 Race/Ethnicity White only Reference Reference Reference Reference Black/African American only 0.83 (0.69-0.99) 0.04 0.78 (0.61-1.01) 0.064 Asian only 0.31 (0.18-0.52) <0.001 0.77 (0.44-1.36) 0.372 Other 1.14 (0.77-1.67) 0.519 1.02 (0.63-1.65) 0.139 Multiracial 1.10 (0.72-1.69) 0.645 1.03 (0.60-1.76) 0.927 Hispanic 0.44 (0.35-0.55) <0.001 0.57 (0.44-0.76) <0.001 BMI Underweight 0.98 (0.66-1.46) 0.914 0.80 (0.48-1.33) 0.388 Normal weight Reference Reference Reference Reference Overweight 1.49 (1.26-1.75) <0.001 1.38 (1.15-1.67) 0.001 Obese 1.85 (1.57-2.18) <0.001 1.63 (1.35-1.97) <0.001 Income < 25,000 2.67 (2.23-3.18) <0.001 2.44 (1.99-3.00) <0.001 25,000-49,999 1.79 (1.48-2.18) <0.001 1.42 (1.14-1.77) 0.002 50,000-74,999 1.35 (1.07-1.69) 0.01 1.16 (0.90-1.48) 0.246 At least 75,000 Reference Reference Reference Reference No Exercise in Past 30 Days 1.85 (1.64-2.09) <0.001 1.42 (1.22-1.66) <0.001 Tobacco use 2.61 (2.31-2.95) <0.001 1.77 (1.51-2.07) <0.001 Alcohol use 0.50 (0.39-0.63) <0.001 0.66 (0.50-0.88) 0.005 Depression 2.17 (1.90-2.49) <0.001 2.19 (1.83-2.62) <0.001

Additional analysis was performed to identify any differences in the baseline characteristics between the individuals that had to be excluded due to missing data and those included. Notably, 87.1% of the excluded participants were under 65 years old, compared to 78.7% for the participants in the study. When analyzing differences in race, there was a higher proportion of Blacks (11.9% vs. 10.9%), Hispanics (24.3% vs. 21.4%), and Asians (12.7% vs. 8.8%) in the excluded group versus included group; however, there was a lower proportion of Whites (47.4% vs. 55.7%). Sex, BMI, income, exercise, tobacco use, and depression all showed similar distributions between each other.

Lastly, a sensitivity analysis was done to check if the association between marijuana use and cardiovascular disease changed assuming that patients with missing information were all marijuana-users (worst-case scenario) or all non-users (best-case scenario). The worst-case scenario was statistically significant (OR: 0.78, 95% CI: 0.62-0.97), compared to the best-case scenario which was not (OR: 0.77, 95% CI: 0.57-1.06).

### Discussion

Marijuana use has been shown to acutely increase cardiac output, affect blood pressure, and sympathetic drive [1-4]. As marijuana use is becoming more accessible through increased legalization, its long-term effects on users are largely unknown. Studies looking at marijuana use, and cardiovascular disease have shown mixed results [3,6,7]; therefore, additional studies looking at such association are warranted.

The primary aim of this study was to evaluate the relationship between marijuana use and cardiovascular disease. After controlling for several confounding variables, we found that there was a decrease in the prevalence of cardiovascular events with marijuana use (OR: 0.74, 95%CI: 0.54,1.01), although it was not a statistically significant result.

A more comprehensive look at similar studies was provided by a systematic review by Ravi et al in 2018, which looked at marijuana use, cardiovascular risk factors, and clinical outcomes [4]. The study looked at a total of 24 separate studies, investigating both cardiovascular risk factors as well as clinical outcomes. Within the review, six of the studies revealed potential metabolic benefits in individuals using marijuana. Such information can be translated back to our study’s findings which could suggest an underlying physiological mechanism that could be cardioprotective. In looking at cardiovascular disease, one study found an increase in myocardial infarction risk in the first hour after smoking marijuana. Another three separate studies all found no association between marijuana use and the incidence of strokes. Finally, four more studies looked at marijuana use and all-cause cardiovascular mortality, but the results of the four studies varied. The overlying conclusion of the review showed insufficient data to make conclusions regarding the effect of marijuana use and negative long-term cardiovascular effects. In contrast, Rumalla et al. conducted a case-crossover study that found marijuana use to cause a 17% increase in the likelihood of hospitalization due to acute ischemic stroke (AIS) [8]. It was also found that the relative risk of individuals was highest among younger adults aged 25-34. This study adjusted for similar covariates to increase the accuracy of the analysis. Differences in findings compared to our study may stem from the fact that this study only focused on one specific form of cardiovascular disease, whereas our study took an umbrella approach to include several types of cardiovascular disease. Additionally, the sample gathered in this study focused on hospitalized patients rather than the general presence of cardiovascular disease. Nonetheless, this study reveals the negative impact that can be seen in people using marijuana.

Since our data was extracted from BRFSS, a national database, gathering the initial dataset was quick and inexpensive. Using secondary data eliminated the need to develop any questionnaires or surveys to collect the data ourselves, which allowed for immediate statistical analysis of the sample generated. Additionally, the sample that was analyzed excluded any patient with missing data for both marijuana use and cardiovascular disease. This aimed to reduce any bias that may stem from these subjects, which could skew any association that may be present. Lastly, we made sure to adjust and control for several covariates (age, income, tobacco use, alcohol use, etc.) to make the most accurate analysis of our data.

Our study had several limitations to note. As a whole, the study was conducted in a retrospective manner, which could affect the validity of the collection process and therefore impact the findings. Additionally, marijuana use was limited to the last 30 days before the completion of the survey. The only BRFSS survey question that gave information relevant to marijuana usage asked how many days the subject used marijuana in the last 30 days. There may have been marijuana users that did not use the drug in the last 30 days, or there may be very seldom users that happened to use it in that same time period. With a limited sample size, we did not break down levels of marijuana use, such as heavy users using marijuana >15 days, light users <15 days, etc. Therefore, not only was it not an exact process grouping marijuana users and non-marijuana users but within the marijuana users’ group, there were varying levels of usage. The sample size was inherently limited due to the fact that the BRFSS survey data regarding marijuana use was limited to only a subset of states. Moreover, the sensitive nature of this question could have impacted the accuracy of reporting.

Furthermore, an additional limitation we recognize is that chronic conditions such as hypertension and diabetes could increase the risk of developing cardiovascular disease. However, the primary aim of our study was to determine the prevalence of diagnosed CVD when surveyed. We do acknowledge the impact this could have had on our results, and therefore we believe further research should include these variables for a more robust analysis of this potential association.

Another limitation was that there was missing data from the BRFSS questionnaire due to participants not fully answering all questions concerning cardiovascular disease and marijuana use. This decreased our sample size from 67,974 to 56,742 subjects. In addition, we recognize that there may have been a subset of respondents who answered "no" to the three questions used to designate subjects as having cardiovascular disease, which could affect the prevalence of our outcome. However, this could also be attributed to our data being gathered from self-reported surveys.

Age, income, and depression were of importance as these variables had odds ratios >2 when linked to cardiovascular disease. As mentioned in the results, our sample had a higher proportion of the excluded data being from a younger subset of individuals. This could have affected prevalence of marijuana use as studies show that younger individuals have had higher odds of being marijuana users [9]. The other two variables, income and depression, showed a similar distribution between subjects included and excluded from the study. Previous studies have shown disparities between racial minority groups compared to whites concerning prevalence of marijuana use. Among these groups, black adults appear to have higher odds of weekly, monthly, and dependence on cannabis use [10]. This may have contributed to the increased proportion of black adults (<65) in the excluded sample compared to the included sample.

Lastly, the answers gathered by subjects through the BRFSS questionnaire are self-reported. There is still a stigma against marijuana use in the United States, especially in the states included in the database that have not legalized it. Given this stigma and the perceived risk of admitting an unlawful behavior, subjects could have been affected by social desirability bias and therefore underreported their use of marijuana. This may have prompted subjects to inaccurately report that they did not use marijuana in the past 30 days.

The link between marijuana use and cardiovascular disease in research is varied. Since our study lacks statistical significance, along with the limitations discussed, further research is implicated to determine if any association exists between marijuana use and cardiovascular disease. As the number of states legalizing marijuana use increases, studies with a similar process should be conducted. This could allow for a more accurate representation of the true prevalence of marijuana use, which would allow future studies to provide increased clinical utility of marijuana use and its impact on cardiovascular disease. Furthermore, because of the link between age and cardiovascular health, as well as the fact that younger age groups are more likely to use marijuana, a confounding variable becomes the age of the participant. As sample sizes grow larger, future studies may want to try to conduct a similar study, but in a specific age group to limit this covariate. Overall clinical significance of marijuana use cannot be fully elucidated given the fact that longitudinal data is still being gathered.

### Conclusions

In conclusion, our study found that there is no link to marijuana use and an increase in cardiovascular disease. Furthermore, there may be a link between marijuana use and lowered risk of cardiovascular disease (OR: 0.74, 95% CI: 0.54-1.01), but the data was not statistically significant when adjusting for confounding variables. This study does, however, implicate the need for future studies with other methods and/or larger sample sizes to provide more insight into this potential association.

### References

1. UNODC: World Drug Report. 2018, UN, New York.
2. Jones RT: Cardiovascular system effects of marijuana. J Clin Pharmacol. 2002, 42:58-63. 10.1002/j.1552-4604.2002.tb06004.x
3. Franz CA, Frishman WH: Marijuana use and cardiovascular disease. Cardiol Rev. 2016, 24:158-162. 10.1097/CRD.0000000000000103
4. Ravi D, Ghasemiesfe M, Korenstein D, Cascino T, Keyhani S: Associations between marijuana use and cardiovascular risk factors and outcomes: a systematic review. Ann Intern Med. 2018, 168:187-194. 10.7326/M17-1548
5. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE: Triggering myocardial infarction by marijuana. Circulation. 2001, 103:2805-2809. 10.1161/01.CIR.103.23.2805
6. Jouanjus E, Raymond V, Lapeyre-Mestre M, Wolff V: What is the current knowledge about the cardiovascular risk for users of cannabis-based products? a systematic review. Curr Atheroscler Rep. 2017, 19:26. 10.1007/s11883-017-0663-0
7. Rodondi N, Pletcher MJ, Liu K, Hulley SB, Sidney S: Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA study). Am J Cardiol. 2006, 98:478-484. 10.1016/j.amjcard.2006.03.024
8. Rumalla K, Reddy AY, Mittal MK: Recreational marijuana use and acute ischemic stroke: a population-based analysis of hospitalized patients in the United States. J Neurol Sci. 2016, 364:191-196. 10.1016/j.jns.2016.01.066
9. Mauro PM, Carliner H, Brown QL, et al.: Age Differences in Daily and Nondaily Cannabis Use in the United States, 2002-2014. J Stud Alcohol Drugs. 2018, 79:423-431. 10.15288/jsad.2018.79.423
10. Wu LT, Zhu H, Swartz MS: Trends in cannabis use disorders among racial/ethnic population groups in the United States. Drug Alcohol Depend. 2016, 165:181-190. 10.1016/j.drugalcdep.2016.06.002

Original article
peer-reviewed

### Author Information

###### Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

###### Acknowledgements

The authors thank faculty and staff at the Florida International University Herbert Wertheim College of Medicine for their collaborative mentorship with this study.

Original article
peer-reviewed

9.0